5-HT1A receptor antagonists(Serotonin 1a (5-HT1a) receptor antagonists), 5-HT2A receptor agonists(Serotonin 2a (5-HT2a) receptor agonists), 5-HT2C receptor agonists(Serotonin 2c (5-HT2c) receptor agonists)

Therapeutic Areas

Other DiseasesNeoplasmsImmune System Diseases+ [6]

Active Indication

Depressive Disorder, MajorDepressive Disorder, Treatment-ResistantBipolar II disorder+ [35]

Inactive Indication

AmnesiaBody Dysmorphic DisordersMild depression+ [2]

Originator Organization-

Active Organization

Compass Pathways Plc

Filament Health Corp.APeT Holding B.V.

+ [30]

Inactive Organization

The University of New Mexico

Cybin, Inc.

Beckley Psytech Ltd.

License Organization

Revive Therapeutics Ltd.Psyence Biomedical Ltd.

Psirenity

+ [15]

Drug Highest PhasePhase 3

First Approval Date-

RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Innovative Licensing and Access Pathway (United Kingdom)

Structure/Sequence

Molecular FormulaC12H17N2O4P

InChIKeyQVDSEJDULKLHCG-UHFFFAOYSA-N

CAS Registry520-52-5

256

Clinical Trials associated with Psilocybin

NCT06005662

/ SuspendedPhase 2IIT

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial

This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care buprenorphine treatment for Opioid use disorder (OUD). Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with buprenorphine maintenance, quality of life, and mood.

Start Date01 Apr 2027

Sponsor / Collaborator

The Johns Hopkins University

ACTRN12625000403437

/ Not yet recruitingPhase 1IIT

A Phase 1, Open-label, Single Cohort Study to Evaluate the Safety and Pharmacokinetics (PK) of a Single Intravenous (IV) Infusion of TRP-8803 [Psilocin Besylate formulation] in Healthy Adult Participants

Start Date01 Sep 2025

Sponsor / Collaborator-

NCT06768944

/ Not yet recruitingPhase 2IIT

The Role of the Stress Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using the Cortisol Synthesis Inhibitor Metyrapone in Healthy Adults

The purpose of this study is to determine the importance in the acute stress response induced by psilocybin (the primary component of "magic mushrooms") in facilitating positive outcomes. Participants in this study will be given psilocybin in combination with a placebo or metyrapone, a cortisol synthesis inhibitor medication, on four different occasions.

Start Date01 Sep 2025

Sponsor / Collaborator

University of Calgary

100 Clinical Results associated with Psilocybin

100 Translational Medicine associated with Psilocybin

100 Patents (Medical) associated with Psilocybin

2,588

Literatures (Medical) associated with Psilocybin

01 Dec 2025·Current Pain and Headache Reports

Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management

Review

Author: Strand, Natalie H ; Gomez, Diego ; Leathem, James ; Viswanath, Omar ; Whitney, Madeline ; Johnson, Brooks ; Attanti, Sumedha ; Maloney, Jillian ; Misra, Lopa ; Dunn, Tyler ; Emami, Eric

PURPOSE OF REVIEW:

Chronic pain affects approximately 1.5 billion people worldwide, representing the leading cause of disability and a significant financial burden on healthcare systems. Conventional treatments, such as opioids and non-steroidal anti-inflammatory drugs, are frequently linked to adverse effects, including dependency and gastrointestinal issues, and often offer limited long-term relief. This review explores the potential of psychedelics, including psilocybin, LSD, and ketamine, as alternative therapeutic agents in chronic pain management.

RECENT FINDINGS:

These substances modulate pain perception through actions on serotonergic and glutamatergic systems and may promote neuroplasticity, offering novel pathways for pain relief. Specifically, the review details the pharmacologic actions of psychedelics, their effects on chronic pain syndromes such as cancer pain, migraines, and neuropathic pain, and their clinical implications. The safety profiles, patient responses, and analgesic properties of these compounds are examined, highlighting the need for further research to validate their efficacy and optimize their therapeutic use in pain management.

01 Dec 2025·Current Pain and Headache Reports

Exploring the Potential of Psychedelics in the Treatment of Headache Disorders: Clinical Considerations and Exploratory Insights

Review

Author: Henderson, Isabella ; Duarte, Robert A ; Vadhan, Nehal P ; Chan, Gabriel ; Elsaadany, Ronnie ; Goodman, Sadie ; Grunstein, Michael ; Duarte, Diana ; Bajaj, Vikram

PURPOSE OF REVIEW:

Exploration of the potential of serotonergic psychedelic drugs, such as psilocybin and LSD, as potential treatments for headache disorders. This review addresses the need for well-informed physician guidelines and discusses mechanisms, safety, and efficacy of these treatments. Further research, including the consideration of combination with psychotherapy, is needed.

RECENT FINDINGS:

Psychedelics demonstrate promising outcomes as treatments for headache disorders. Recent findings indicated that some patients who underwent brief periods of treatment with psychedelics experienced a reduction in headache attack frequency, severity, or duration. When prescription medications are ineffective at treating headache disorders, or are habit-forming, patients often turn to alternative options. There is anecdotal evidence that psychedelic drugs like LSD and psilocybin can effectively treat and prevent pain in patients with headache disorders, such as migraine or cluster headache. It is vital that physicians treating patients who self-treat with psychedelics be well-informed about the mechanisms and their effects to best advise their patients and coordinate their care well. This is a review assessing the literature on the mechanisms, safety, and efficacy of psychedelic drugs as a headache management intervention. We believe there is evidence that may support further investigation into the clinical use of psychedelic medications to treat cluster headache and migraine, including the consideration of use in conjunction with other interventions like cognitive behavioral therapy or acceptance and commitment training.

01 Dec 2025·HUMAN & EXPERIMENTAL TOXICOLOGY

Insights into therapeutic potential and practical applications of natural toxins from poisonous mushrooms

Review

Author: Xu, Baojun ; Wijesekara, Tharuka

Introduction:

Mushrooms, belonging to the phyla Ascomycota and Basidiomycota, comprise approximately 14,000 known species, among which a small fraction are toxic. While toxic mushrooms are primarily associated with adverse health effects, recent research highlights their potential as sources of bioactive compounds with promising therapeutic applications.

Methods:

A systematic review was conducted using four major electronic databases: Web of Science, Google Scholar, PubMed, and ScienceDirect. The literature search, completed on July 1, 2024, utilized keywords including “Poisonous mushrooms,” “Mushroom toxins,” “Mycotoxins,” “Beta-glucans,” “Psilocybin,” and “Therapeutic applications.” Articles were selected based on specific inclusion criteria, focusing on studies investigating the biochemical, toxicological, and pharmacological properties of toxic mushroom compounds. Studies unrelated to mushrooms, non-peer-reviewed sources, or those with outdated or incomplete data were excluded.

Results:

This review examines key toxic mushroom compounds such as amanitins, phallotoxins, ibotenic acid, muscimol, orellanine, and gyromitrin, emphasizing their biosynthesis, structural features, and health effects. Despite their toxicity, compounds like beta-glucans, polysaccharides, lectins, and psilocybin exhibit immune-modulating, anticancer, and neuroprotective properties. These bioactive compounds have shown promise in targeting cancer stem cells and enhancing neurotransmitter activity, positioning them as potential therapeutic agents.

Discussion:

Understanding the therapeutic potential of toxic mushroom-derived bioactive compounds bridges toxicology and pharmacology, offering novel avenues for drug discovery. Comparative analysis with existing treatments highlights their unique advantages in modern medicine.

998

News (Medical) associated with Psilocybin

16 May 2025

·www.globenewswire.com

BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders

May 14, 2025 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders, recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. BetterLife reported that its proprietary compound, BETR-001, is showing very promising preclinical data of its breakthrough ability to provide therapeutic effect in depression/anxiety animal models. Current methods of treating depression/anxiety primarily focus on increasing the level of one of the three neurotransmitters: serotonin, norepinephrine and/or dopamine in the brain. Each neurotransmitter has different receptor targets, and each receptor performs different functions. Current treatments are usually reuptake inhibitors such as SSRIs (selective serotonin reuptake inhibitors) and by increasing the amount of a neurotransmitter, all its receptors are activated. What is needed are new treatments that activate the neuroreceptors themselves, and more importantly, only selective subsets of these receptors. The therapeutic effects of BETR-001 seen in preclinical models are primarily driven by its activation (agonism) of serotonin’s 5HT2A receptor. Not only does BETR-001 activate the 5HT2A receptor, which plays a key role in depression/anxiety, this activation is via a mechanism that allows for a highly efficacious therapeutic effect without hallucinogenic side effects. This stands in contrast to other potent 5HT2A activators, such as LSD, psilocybin and other psychedelics. BetterLife has reported on the details of BETR-001 activation of the 5HT2A receptor previously (Lewis et al., Cell Reports, 2023). Recently studies have shown that the activation of the 5HT2A receptor above 70% leads to hallucination (Wallach et al., Nature Communications, 2023). Ideally, a therapeutic agent should activate 5HT2A but stay below the 70% threshold. BETR-001 fulfills this parameter perfectly: activating 5HT2A maximally to 60%, unlike LSD, which activates 5HT2A to near 90%. This is shown in our 5HT2A receptor activation data below, where the X-axis is an increasing amount of the drug, and the Y axis is the percentage activation of the 5HT2A receptor. The drugs tested are 5-HT (the parent serotonin), LSD and BETR-001. BetterLife believes that BETR-001’s novel mechanism of action provides a new paradigm for treatment of psychiatric disorders such as depression, anxiety and PTSD. It activates the 5HT2A receptor partially but stays below the hallucination threshold. In addition, unlike LSD, psilocybin, MDMA and other such agents BETR-001 is not an activator of the 5HT2B receptor. Activation of 5HT2B has been linked to cardiac safety. The neuroreceptor selectivity of BETR-001 in this regard is another of its key advantages over other competitor agents. An additional benefit of BETR-001 is that repeated dosing does not induce tolerance, unlike classic agents like LSD. This allows daily administration if needed. Furthermore, the lack of hallucinations with BETR-001 means it is a non-controlled substance and patient self-administration at home is possible. Finally, an overarching property of BETR-001 is that it is a very potent neuroplastogen. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO (BetterLife press release January 14, 2025). BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for H1 2026. BetterLife is considering the development of BETR-001 for treatment of various psychiatric and neurological disorders. BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic neuroplastogen. BETR-001 is a non-controlled substance. BETR-001 will be developed for the treatment of various psychiatric and neurological disorders. BETR-001 pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders. BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s pending method of use and formulations patent covers treatment of anxiety-related disorders including benzodiazepine dependency. BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development. The content above comes from the network. if any infringement, please contact us to modify.

08 May 2025

·www.filament.health

Filament Health Announces First Quarter 2025 Financial Results And Operational Highlights

Vancouver, British Columbia, May 8, 2025 – Filament Health Corp. (OTCQB:FLHLF) (CBOE:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, released its first quarter financial results and operational highlights for the period ended March 31, 2025. “This quarter we were pleased to see positive data from a clinical trial studying our botanical psilocybin drug candidate, PEX010, for alcohol use disorder at Psychiatric Centre Copenhagen, among other notable operational developments,” said Benjamin Lightburn, Co-Founder and Chief Executive Officer at Filament Health. “We were also encouraged by the successful completion of a meaningful fundraising round. This progress demonstrates our team’s resilience and commitment to advancing our mission.” Recent and Q1 2025 Financial and Operational Highlights: - On April 9, 2025, the Company announced FDA authorization of a phase 2 clinical trial studying PEX010, the Company's botanical psilocybin drug candidate, for the treatment of opioid use disorder at the University of Pennsylvania. - On April 9, 2025, the Company closed a financing of $960,000 further to the issuance of units, comprised of a secured convertible debenture of the company and a warrant. - On March 17, 2025, the Company announced that a licensing partner studying the effects of its botanical psilocybin drug candidate, PEX010, for the treatment of alcohol use disorder (“AUD”) produced positive data and results were published in the Journal of Psychopharmacology noting the safety and efficacy in reducing alcohol consumption in AUD patients. - On January 21, 2025, the Company announced the shipment of botanical psilocybin to The University of Wisconsin-Madison for investigation in two US Food and Drug Administration-approved clinical trials studying the effects of psilocybin on neuroplasticity. - Cash and cash equivalents of $130,441 as of March 31, 2025; - Cash used in operating activities of $221,755 and total revenues of $103,480. Special Shareholder Meeting At a special shareholder meeting held on May 6, 2025, 99.625 percent of votes were cast in favour of the voluntary de-listing of the company’s common shares from Cboe Canada. This strong support reflects shareholder alignment with the company's strategic direction and ongoing efforts to reduce operating costs. The Company is in active discussions with CBOE Canada regarding the de-listing and will share more information, such as when the Company’s shares will be de-listed, as it becomes available. Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates. Learn more at www.filament.health and on Twitter, Instagram and LinkedIn. Anna Cordon, Vice President, Marketing & Communications anna@filament.health ir@filament.health Certain statements and information contained herein may constitute “forward-looking statements” and “forward-looking information,” respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward-looking statements or information. Forward-looking statements herein include, but are not limited to, statements regarding the benefits of psilocin as compared to psilocybin. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. Forward-looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including results of the clinical trial. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws. ‍

Financial StatementPhase 2License out/in

08 May 2025

·www.otsuka.co.jp

Otsuka Signs Joint Research Agreement with Keio UniversityIndustry-academia collaboration for infrastructure development toward the social implementation of psychedelics in Japan

RSS Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announces that it has signed a basic research (non-clinical research) agreement with Keio University (Keio) for infrastructure development toward the social implementation of psychedelics in Japan. Conventional treatments for depression, anxiety, obsessive-compulsive disorder, and post-traumatic stress disorder (PTSD)--such as antidepressants, augmentation therapy, and cognitive behavioral therapy--are often insufficient in terms of treatment efficacy and relapse prevention. As a result, many patients and their families suffer from the illness and associated decline in social functioning. Economic and social losses are also significant, and there is a strong demand for the development of new treatments for refractory mental disorders. Furthermore, clinical trial results conducted outside Japan on psychedelics such as psilocybin have indicated long-lasting antidepressant effects (6 to 12 months) with just one or two doses. Psilocybin acts as a 5-HT2A receptor agonist and has been confirmed to have a strong and fast-acting antidepressant effect.*1,2 Treatments using psychedelics have been designated as breakthrough therapies in the United States, with multiple pharmaceutical companies conducting phase 3 trials. Phase 2 trials are also underway in Europe. In contrast, in Japan, no clinical trials for psychedelic candidates have been conducted. Only small-scale specific clinical research, led by Professor Hiroyuki Uchida of the Department of Psychiatry and Neuroscience at Keio University School of Medicine, is being carried out with a research grant from the Japan Agency for Medical Research and Development (AMED) under the Research and Development Grants for Comprehensive Research for Persons with Disabilities (in the field of mental disorders) program. In order to safely and appropriately deliver psychedelics to patients in Japan, numerous challenges must be addressed for successful social implementation, as listed below. Key issues for social implementation of psychedelics ・ Optimal clinical trials designed to maximize the therapeutic potential of psychedelics ・ Establishment of a system for the professional development of psychiatrists and psychologists and the development of a system for implementing medical institutions ・ Addressing legal and ethical issues and regulatory compliance related to the use of psychedelics ・ Public awareness campaigns to correct social prejudices and misconceptions about psychedelics Otsuka and Keio have outlined several development items in their joint basic research to deliver psychedelics developed overseas to patients in Japan in the future. These items include consideration of development policies for psychedelics, formulating treatment manuals and guidelines, developing expert training programs, addressing legal and ethical issues, conducting public relations and public awareness campaigns, and promoting corporate collaboration and intellectual property strategies. Otsuka and Keio are committed to addressing these challenges to establish a new standard for treating mental disorders in Japan through the clinical application of psychedelics. *1 Gukasyan N et al. J Psychopharmacol. 2022;36:151-158 *2 Carhart-Harris RL et al. Lancet Psychiatry. 2016;3:619-627; Goodwin G, et al. N Engl J Med. 2022;387:1637-1648

Phase 2Breakthrough TherapyPhase 3

100 Deals associated with Psilocybin

External Link

KEGG	Wiki	ATC	Drug Bank
-	Psilocybin	-	DB11664

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Depressive Disorder, Major	Phase 3	United States	Usona Institute	05 Mar 2024
Depressive Disorder, Treatment-Resistant	Phase 3	United States	Compass Pathways Plc	19 Jan 2023
Stimulant abuse	Phase 2	-	Filament Health Corp.	01 Jan 2025
Opioid abuse	Phase 2	-	Filament Health Corp.	01 Dec 2024
Irritable Bowel Syndrome	Phase 2	United States	Tryp Therapeutics, Inc.	17 Jan 2024
Borderline Personality Disorder	Phase 2	United States	Usona Institute	01 Nov 2023
Neoplasms	Phase 2	United States	Sunstone Medical LLC	23 Oct 2023
Fibromyalgia	Phase 2	United States	University of Michigan	27 Sep 2023
Generalized anxiety disorder	Phase 2	Canada	Diamond Therapeutics, Inc.	24 Jan 2023
Mild depression	Phase 2	Canada	-	01 Jan 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05847686 (CTgov)	Phase 1/2	Neoplasm Metastasis \| Metastatic Solid Tumor \| Hematologic Neoplasms ... View more	55	Counseling+Psilocybin	ldujwrqypu = ogamrgboqa zwxqeuhsxz (qfkivsukkm, amarwamgin - zrfhzgusop) View more	-	30 Apr 2025
NCT05128162 (CTgov)	Phase 2	Fibromyalgia	17	Psilocybin	uiasbrhvcm(wkmwvrrheu) = xhfpfpbbql atkbdxnkky (htmpfmabgp, acoksnnnur - znwnwxckpo) View more	-	16 Apr 2025
NCT04141501 (Pubmed \| EClinicalMedicine)	Phase 2	Alcohol Use Disorder	37	Psilocybin (25 mg)	sflkishsvm(lssppcpphb) = bqaievwasy xnrcgmjnvf (udzquwskck, 14.31 - 19.29) View more	Negative	01 Apr 2025
NCT04141501 (Pubmed \| EClinicalMedicine)	Phase 2	Alcohol Use Disorder	37	Placebo (mannitol)	sflkishsvm(lssppcpphb) = pddlsxtcvf xnrcgmjnvf (udzquwskck, 10.97 - 16.63) View more	Negative	01 Apr 2025
NCT05163496 (CTgov)	Phase 3	Post Acute COVID 19 Syndrome \| Burnout, Professional \| Stress Disorders, Post-Traumatic	30	Psilocybin (Psilocybin Arm)	tzjikahsne(qwtcunbyzk) = qxoazydaoe cipzlprcwk (bpxnijcbwj, 7.84) View more	-	18 Mar 2025
NCT05163496 (CTgov)	Phase 3		30	Active placebo (Placebo)	tzjikahsne(qwtcunbyzk) = lsumebbglx cipzlprcwk (bpxnijcbwj, 7.32) View more	-	18 Mar 2025
NCT04718792 (Company_Website \| Pubmed) Manual	Phase 2	Alcohol Use Disorder	10	PEX010	znsgwtflzw(hijrbbyrue) = ktvfqcqemx isypmoxtiq (cyatxawqhs, −61.1 - −13.9) View more	Positive	17 Mar 2025
NCT04433858 (Pubmed \| J Affect Disord)	Phase 2	Depressive Disorder, Treatment-Resistant	15	Psilocybin 25 mg	gpbuuesssc(kwpqqpujpj) = ltowyefosz ywgfrvfdyh (bhqkmkklkk ) View more	Positive	01 Jan 2025
NCT03429075 (Psilodep-RCT, CTgov)	Phase 2	Depressive Disorder, Major	59	Psilocybin + Placebo (Psilocybin)	vkrytrihph(gszekhluxn) = dltvaslkpx vhfjiitypg (hxhcxrrhtl, 0.45) View more	-	24 Oct 2024
NCT03429075 (Psilodep-RCT, CTgov)	Phase 2	Depressive Disorder, Major	59	Psilocybin + Escitalopram (Escitalopram)	vkrytrihph(gszekhluxn) = heykzczamj vhfjiitypg (hxhcxrrhtl, 0.62) View more	-	24 Oct 2024
NCT03429075 (Literature) Manual	Phase 2	Major depressive disorder, moderate (MDD)	59	Psilocybin combined with psychological support	sxkqscbzam(jvardrrwsp): Difference = 1.51 (95% CI, -1.35 to 4.38), P-Value = 0.311 View more	Positive	21 Sep 2024
NCT03429075 (Literature) Manual	Phase 2	Major depressive disorder, moderate (MDD)	59	Escitalopram combined with psychological support		Positive	21 Sep 2024
NCT04661514 (Pubmed)	Phase 1	Anorexia Nervosa	10	Psilocybin	jpiuitakak(ydcldeyaom) = Two participants developed asymptomatic hypoglycemia at post-treatment, which resolved within 24 h. No other clinically significant changes were observed in laboratory values. All AEs were mild and transient in nature. bwnhmoujxn (mhhocapckw )	Positive	01 Jul 2024
NCT05312151 (GlobeNewswire) Manual	Phase 2	Stress Disorders, Post-Traumatic	22	COMP360 psilocybin	kkmhiclxuf(ftxbbqawrt) = There were no treatment-emergent serious adverse events. uaislvefkp (lptwyunugi ) Met View more	Positive	08 May 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Psilocybin

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation